scholarly journals A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis

2001 ◽  
Vol 84 (1) ◽  
pp. 76-81 ◽  
Author(s):  
D I Johnston
Keyword(s):  
Growth Hormone ◽  
Turner Syndrome ◽  
Low Dose ◽  
Multicentre Trial ◽  
Final Height ◽  
Recombinant Growth Hormone

scholarly journals Growth Hormone and Low Dose Estrogen in Turner Syndrome: Results of a United States Multi-Center Trial to Near-Final Height

2002 ◽  
Vol 87 (5) ◽  
pp. 2033-2041 ◽  
Author(s):  
Charmian A. Quigley ◽  
Brenda J. Crowe ◽  
D. Greg Anglin ◽  
John J. Chipman
Keyword(s):  
United States ◽  
Growth Hormone ◽  
Turner Syndrome ◽  
Low Dose ◽  
Final Height

Therapeutic effects of growth hormone combined with low-dose stanozolol on growth velocity and final height of girls with Turner syndrome

2015 ◽  
Vol 83 (2) ◽  
pp. 223-228 ◽  
Author(s):  
Hui Xiong ◽  
Hong-Shan Chen ◽  
Min-Lian Du ◽  
Yan-Hong Li ◽  
Hua-Mei Ma ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Turner Syndrome ◽  
Growth Velocity ◽  
Low Dose ◽  
Final Height ◽  
Therapeutic Effects

scholarly journals Adult Heights of 258 Girls with Turner Syndrome on Low Dose of Growth Hormone Therapy in Japan

2010 ◽  
Vol 19 (3) ◽  
pp. 63-68 ◽  
Author(s):  
Keinosuke Fujita ◽  
Susumu Yokoya ◽  
Kenji Fujieda ◽  
Akira Shimatsu ◽  
Katsuhiko Tachibana ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Turner Syndrome ◽  
Low Dose ◽  
Growth Hormone Therapy

scholarly journals Final Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment in Three Dosages and Low Dose Estrogens

2003 ◽  
Vol 88 (3) ◽  
pp. 1119-1125 ◽  
Author(s):  
Yvonne K. van Pareren ◽  
Sabine M. P. F. de Muinck Keizer-Schrama ◽  
Theo Stijnen ◽  
Theo C. J. Sas ◽  
Maarten Jansen ◽  
...  
Keyword(s):  
Turner Syndrome ◽  
Low Dose ◽  
Final Height ◽  
Height Velocity ◽  
Chronological Age ◽  
First Year ◽  
Bone Maturation ◽  
Gh Treatment ◽  
Group A ◽  
Group B

Although GH treatment for short stature in Turner syndrome is an accepted treatment in many countries, which GH dosage to use and which age to start puberty induction are issues of debate. This study shows final height (FH) in 60 girls with Turner syndrome treated in a randomized dose-response trial, combining GH treatment with low dose estrogens at a relatively young age. Girls were randomly assigned to group A (4 IU/m2·d; ∼0.045 mg/kg/d), group B (first year, 4 IU/m2·d; thereafter 6 IU/m2·d), or group C (first year, 4 IU/m2·d; second year, 6 IU/m2·d; thereafter, 8 IU/m2·d). After a minimum of 4 yr of GH treatment, at a mean age of 12.7 ± 0.7 yr, low dose micronized 17β-estradiol was given orally. After a mean duration of GH treatment of 8.6 ± 1.9 yr, FH was reached at a mean age of 15.8 ± 0.9 yr. FH, expressed in centimeters or sd score, was 157.6 ± 6.5 or −1.6 ± 1.0 in group A, 162.9 ± 6.1 or −0.7 ± 1.0 in group B, and 163.6 ± 6.0 or −0.6 ± 1.0 in group C. The difference in FH in centimeters, corrected for height sd score and age at start of treatment, was significant between groups A and B [regression coefficient, 4.1; 95% confidence interval (CI), 1.4, 6.9; P < 0.01], and groups A and C (coefficient, 5.0; 95% CI, 2.3, 7.7; P < 0.001), but not between groups B and C (coefficient, 0.9; 95% CI, −1.8, 3.6). Fifty of the 60 girls (83%) had reached a normal FH (FH sd score, more than −2). After starting estrogen treatment, the decrease in height velocity (HV) changed significantly to a stable HV, without affecting bone maturation (change in bone age/change in chronological age). The following variables contributed significantly to predicting FH sd score: GH dose, height sd score (ref. normal girls), chronological age at start of treatment, and HV in the first year of GH treatment. GH treatment was well tolerated. In conclusion, GH treatment leads to a normalization of FH in most girls, even when puberty is induced at a normal pubertal age. The optimal GH dosage depends on height and age at the start of treatment and first year HV.

Efficacy of intermittent therapy in growth hormone-deficient children

1994 ◽  
Vol 130 (5) ◽  
pp. 459-462 ◽  
Author(s):  
Pierre Bougnères
Keyword(s):  
Growth Hormone ◽  
Final Height ◽  
Continuous Treatment ◽  
First Year ◽  
Intermittent Therapy ◽  
Recombinant Growth Hormone ◽  
Growth Hormone Administration ◽  
Hormone Administration ◽  
Height Gain ◽  
Initiation Of Therapy

Bougnères P. Efficacy of intermittent therapy in growth hormone-deficient children. Eur J Endocrinol 1994;130:459–62. ISSN 0804–4643 Eighty-six growth hormone-deficient children treated with extractive growth hormone were transferred to recombinant growth hormone (rGH): 57 children were transferred directly to rGH, but 29 experienced a 9.7 ± 1-month pause in growth hormone administration. The retrospective analysis of growth from 1 year before to 1 year after initiation of rGH showed that the interruption of growth hormone administration did not modify the final height gain. During the 2 years, children with continuous therapy gained 12.2 ± 0.5 cm with a cumulative growth hormone dose of 43 ± 3 U/kg, while those who paused gained 12.1 ±0.3 cm with a cumulative growth hormone dose of only 24 ± 2 U/kg (p < 0.0005). As expected, during the year preceding the onset of rGH, the children who paused gained less height than those treated continuously, but grew more rapidly during the first year of rGH administration. This was due to an important re-acceleration of growth rate at re-initiation of therapy after the pause. Our observation suggests that regimens of discontinuous rGH administration could be as efficient as continuous treatment. If confirmed in prospective randomized trials, this could have important consequences for improving the clinical efficiency of a given dose of rGH, as well as for the patient's comfort, secondary effects and cost of therapy. Pierre Bougnères, Service d'Endocrinologie Pédiatrique, Hôpital Saint Vincent de Paul, 82 avenue DenfertRochereau, 75014 Paris, France

Sign in / Sign up

Export Citation Format

Share Document